Amgen Monday consensus picture, shares hold near recent highs
29.06.2026 - 20:26:53 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 20:26.
Amgen Inc. (US0311621009) begins the new week with a relatively stable share price and a well-defined analyst consensus on Nasdaq. The biotechnology group remains one of the larger constituents of the S&P 500 health-care cohort, with investors watching valuation metrics and pipeline news closely.
Where Amgen shares trade now
On Nasdaq, Amgen shares most recently traded around 358 dollars, with intraday highs near 362 dollars and lows around 354 dollars, according to Investing.com price data. Daily volume stood at roughly 3.6 million shares, reflecting moderate activity compared with some of its U.S. large-cap peers. The current level leaves the stock close to the upper band of its recent range rather than at a marked low, a stance that tends to focus investor attention on upcoming catalysts.
With a market capitalization in the area of 190 billion dollars on recent figures, Amgen sits alongside other global biopharmaceutical heavyweights such as AbbVie and Bristol Myers Squibb. The company is part of the S&P 500 and the Nasdaq-100, so its shares play into major index-tracking portfolios and sector exchange-traded funds that reference the U.S. biotech and big pharma space.
Analyst ratings and targets on Amgen
Across the broader analyst community, Amgen is typically covered by more than 20 sell-side firms, with most recent data on MarketScreener indicating a majority of Buy or Outperform recommendations and a smaller group of Hold ratings. The average twelve-month price target on that platform has been reported in a corridor somewhat above the current share price, implying limited but positive expected upside based on consensus modelling. Individual houses, including major players such as Goldman Sachs and Morgan Stanley, regularly update their assumptions as new clinical and commercial data emerge, although no major rating change has been reported by top-tier houses in the very latest session.
Different analysts emphasize different elements of the investment case: some focus on Amgen's ability to generate robust free cash flow and maintain its dividend, while others highlight the need to offset potential erosion in mature products through new launches and acquisitions. For retail investors, the key takeaway is that the stock sits in a zone where professional valuations are relatively anchored, not at the extremes of the typical rating scale or price-target dispersion.
All news and analysis on the Amgen shares
Follow further reports, analyst commentary and corporate filings on Amgen to understand how new data points may shift sentiment around the shares.
How upcoming dates shape attention
According to Amgen's investor relations calendar, the company typically reports its quarterly results around late July or early August for the second quarter, although the precise next earnings date has yet to be formally posted for the current cycle. Earnings calls usually combine headline financial figures with updates on key products and pipeline readouts, giving analysts fresh material for revised models. In addition, investor days or conference appearances at health-care meetings can add detail on clinical progress in oncology, inflammation and other focus areas.
For holders of Amgen shares, dividend timing is another recurring element. The company has a history of paying a regular quarterly dividend and announcing adjustments in connection with its broader capital-allocation plans. Analysts will watch how management balances shareholder returns with investment in research, licensing deals and possible bolt-on acquisitions, especially as competition in major disease areas remains intense.
What the company sells
Amgen generates most of its revenue from biopharmaceuticals addressing serious diseases, with products spanning areas such as oncology, inflammation, bone health and cardiovascular risk. A prominent example is Repatha, a PCSK9 inhibitor used to help lower LDL cholesterol in patients who need additional support alongside statins.
Where the stock trades today
Amgen shares trade on Nasdaq under the ticker AMGN, with a recent price around 358 dollars as of 2026-06-29, 20:10, based on Investing.com data. This level places the stock among the higher-priced constituents of the U.S. large-cap biopharma group, reflecting its established position and pipeline expectations.
Amgen at a glance
- Company: Amgen Inc.
- ISIN: US0311621009
- WKN: 867177
- Ticker: AMGN
- Trading venue: Nasdaq
- Price (as of 2026-06-29, 20:10): 358 USD
- Market cap: approximately 190 billion USD (as of 2026-06-29)
- Sector / industry: Health Care - Biotechnology
- Index membership: S&P 500, Nasdaq-100
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
